Insulet this morning issued a press release indicating that it was pausing the pivotal trial on its key new product known as Horizon. This update is a bit surprising as management said last week that everything was on schedule with Horizon, but this is another example that clinical studies are difficult to predict, Piper Sandler analyst Matt O'Brien tells investors in a research note. While the news is frustrating, Insulet has a good handle on the issue and the delay will be modest at a couple of months, contends the analyst. As such, he believes investors should take advantage of the weakness today in the shares "in what will likely be a short-term, transitory issue." O'Brien reiterates an Overweight rating on Insulet with a $200 price target. The stock in premarket trading is down 7%, or $12.97, to $177.00.